Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers ...

The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space ...

Sionna Therapeutics is eyeing a $156 million IPO as the cystic-fibrosis-focused biotech looks to take its lead candidate into ...

It also has activity against 31 CFTR variants — carried by around 150 cystic fibrosis patients in the US — that are not responsive to the older combination therapy. The new combination was ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...

“Beyond tobacco, increasing attention should be given to the environmental and occupational factors that ... for molecular testing and personalized therapy in all lung cancer patients, as ...

Please provide your email address to receive an email when new articles are posted on . Percent-predicted FEV 1, sweat chloride and safety were analyzed in two phase 3 trials of vanzacaftor ...

Louise Patterson, from Bray, is the mother of Aaron, who will soon be 12. His rare gene means he is currently excluded from modulator therapy Kaftrio, which, when combined with other medication ...

This condition is part of a broader category of occupational lung diseases that also includes silicosis and progressive massive fibrosis (PMF). Recent research has focused on understanding the ...

A Wicklow mother is among a concerned group of parents who are calling for individual trials of the modulator therapies for their children with Cystic Fibrosis who still do not have access to these ...

For decades, Japan’s work culture was synonymous with gruelling hours and self-sacrifice. But a quiet revolution appears to be under way: younger Japanese workers are clocking fewer hours than ...

Skin fibrosis is an often-painful condition wherein the skin thickens and hardens, making it difficult to move. And with no effective treatments currently available, patients are left with few avenues ...